EURONEUT-41
EUROpean consortium on NEUTralising antibodies using gp41
| Coordinatore | SANOFI PASTEUR SA
Organization address
address: "Avenue Pont Pasteur, 2" contact info |
| Nazionalità Coordinatore | France [FR] |
| Totale costo | 15˙922˙033 € |
| EC contributo | 11˙966˙082 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-A |
| Funding Scheme | CP-IP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-01-01 - 2014-03-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
SANOFI PASTEUR SA
Organization address
address: "Avenue Pont Pasteur, 2" contact info |
FR (LYON) | coordinator | 0.00 |
| 2 |
"Royal Free Hospital, Royal Free Hampstead NHS Trust"
Organization address
address: Pond street contact info |
UK (LONDON) | participant | 0.00 |
| 3 |
BIONEER A/S
Organization address
address: KOGLE ALLE 2 contact info |
DK (HOERSHOLM) | participant | 0.00 |
| 4 |
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
Organization address
address: RUE LEBLANC 25 contact info |
FR (PARIS 15) | participant | 0.00 |
| 5 |
GENEART AG
Organization address
address: Josef-Engert-Strasse 11 contact info |
DE (REGENSBURG) | participant | 0.00 |
| 6 |
IM PROJET (SUISSE) SARL
Organization address
address: RUE DE LA FONTENETTE 29 contact info |
CH (CAROUGE) | participant | 0.00 |
| 7 |
IM PROJET SAS
Organization address
address: PORTE DU GRAND LYON 6 contact info |
FR (NEYRON) | participant | 0.00 |
| 8 |
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD contact info |
UK (LONDON) | participant | 0.00 |
| 9 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 0.00 |
| 10 |
LES CENTRES GHESKIO
Organization address
address: 33 BOULEVARD HARRY TRUMAN contact info |
HT (PORT-AU-PRINCE) | participant | 0.00 |
| 11 |
MEZOGAZDASAGI SZAKIGAZGATASI HIVATAL KOZPONT
Organization address
address: Szallas 8 contact info |
HU (BUDAPEST) | participant | 0.00 |
| 12 |
POLYMUN SCIENTIFIC IMMUNBIOLOGISCHE FORSCHUNG GMBH
Organization address
address: DONAUSTRASSE 99 contact info |
AT (KLOSTERNEUBURG) | participant | 0.00 |
| 13 |
PX'Therapeutics
Organization address
address: "15, rue des Martyrs" contact info |
FR (GRENOBLE) | participant | 0.00 |
| 14 |
QUEEN'S UNIVERSITY BELFAST
Organization address
address: University Road contact info |
UK (BELFAST) | participant | 0.00 |
| 15 |
ROBERT KOCH-INSTITUT
Organization address
address: Nordufer 20 contact info |
DE (Berlin) | participant | 0.00 |
| 16 |
ST GEORGE'S HOSPITAL MEDICAL SCHOOL
Organization address
address: Cranmer Terrace contact info |
UK (LONDON) | participant | 0.00 |
| 17 |
UNIVERSIDAD DE GRANADA
Organization address
address: CUESTA DEL HOSPICIO SN contact info |
ES (GRANADA) | participant | 0.00 |
| 18 |
UNIVERSITE DE STRASBOURG
Organization address
address: rue Blaise Pascal 4 contact info |
FR (Strasbourg) | participant | 0.00 |
| 19 |
UNIVERSITY OF SURREY
Organization address
address: Stag Hill contact info |
UK (GUILDFORD) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'There is now an increasingly solid body of scientific evidence which demonstrates that the binding of small molecular weight compounds, peptides and antibodies (Abs) to fusion-intermediate conformations of gp41 leads to an inhibition of HIV cell entry. The principal aim of this project is to exploit this information by establishing a platform where gp41-derived vaccine candidates will be designed to elicit neutralising Abs. Several families of immunogens which mimic gp41 in its fusion intermediate conformations are already available and others will be designed using modelisation approaches. Candidates will be submitted to a thorough biophysical characterisation followed by a preclinical development in order to identify the most promising for clinical evaluation. A crucial selection parameter is the capacity of antigens to elicit neutralising Abs using internationally standardized assays. Since sexual transmission accounts for more than 90% of HIV infection, the capacity of Abs to inhibit infection at the mucosal level will also be determined. This cross-disciplinary project gathers top European scientists with expertise in protein engineering and characterisation, adjuvantation, formulation for systemic and mucosal delivery, evaluation of functional antibody response, efficacy testing in animal models, medium to large scale vaccine production as well as conduct of clinical trials in both developed and third-world countries. In contrast to previous more empirical attempts, this project is based on the rational exploitation of the knowledge on the mechanism of HIV entry and is thus a promising approach to generate a protective vaccine. It will be the first European project targeting intermediate conformations of gp41 and it could complement/synergize other international strategies focusing on the membrane proximal region of gp41 or gp140 trimer to induce neutralising Abs or aiming at reducing the viral load by eliciting a cellular immunity against HIV.'
Introduzione (Teaser)
A European consortium is tackling HIV infection by generating neutralising antibodies. This is expected to act as a preventive vaccine blocking entry of the virus into the cell.